<h4>Background</h4>Despite multiple phase III randomized controlled trials (RCTs) establishing first-line treatments for advanced anaplastic lymphoma kinase (ALK) rearrangement non-small cell lung cancer (NSCLC), the optimal regimen for diverse clinicopathological features remains unclear.<h4>Methods</h4>PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched for RCTs. Here, ALK is linked to non-small cell lung carcinoma.